This study revealed that in the era of anti-HER2 targeted therapy, HER2-overexpressing breast cancer with 1-3 positive axillary lymph nodes and positive hormone receptor status has gradually evolved into a clinically low-risk subtype. The gene discussed is NR4A1; the disease is breast cancer.